June 13 2024
Recently reported results from the NRG-GOG 0238 clinical trial that tested radiotherapy with or without cisplatin-based chemotherapy for recurrences in endometrial cancer indicated that radiotherapy should remain the standard of care for this population. Patients treated with chemotherapy and radiotherapy experience higher acute toxicities without improvement in progression-free survival as compared to patients treated with radiotherapy alone. These results were published in Journal of Clinical Oncology.
“Endometrial cancer is the most common gynecologic cancer in the United States and pelvic recurrence is a frequent pattern of relapse for women with this disease. While NRG-GOG 0238 did not determine that chemoradiotherapy was the better treatment option, this study helped define radiotherapy with brachytherapy as the current standard of care. Analysis of molecular subsets of tumors may better define the optimal therapy for women with recurrent endometrial cancer,” stated Ann Klopp, MD, of the University of Texas MD Anderson Cancer Center and the lead author of the NRG-GOG 0238 manuscript.
NRG-GOG 0238 accrued 165 women with endometrial cancer and randomly assigned them (1:1) to receive either radiotherapy or chemoradiotherapy. The median PFS was longer for patients treated with radiotherapy alone (median PFS was not reached for the radiotherapy arm versus 73 months for the chemoradiotherapy arm). After 3 years, 73% of patients treated with radiotherapy alone and 62% of patients treated with chemoradiotherapy were alive and free of disease.
Read the full article on ASCO Pubs. (subscription or purchase required)